648934-56-9

Upstream product

• 5211-24-5 (2S)-2,5-dihydro-1H-pyrrole-1,2-dicarboxylic acid 2-methyl 1-(phenylmethyl) ester 
• 648934-51-4 (3aR,6S,6aS)-4-benzoyl-1-[(2S)-2-(4-tert-butylbenzoylamino)-4-methylpentanoyl]-6-hydroxyhexahydropyrrolo[3,2-c]pyrazole-2-carboxylic acid tert-butyl ester 
• 648934-49-0 (3aR,6S,6aS)-1-[(2S)-2-(4-tert-butylbenzoylamino)-4-methylpentanoyl]-6-hydroxyhexahydropyrrolo[3,2-c]pyrazole-2,4-dicarboxylic acid 4-benzyl ester 2-tert-butyl ester 
• 648934-45-6 (2S)-2-{N-tert-butoxycarbonyl-N'-[(2S)-2-(4-tert-butylbenzoylamino)-4-methylpentanoyl]-hydrazinomethyl}-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-38-7 (2S)-2-[N'-((2S)-2-allyloxycarbonylamino-4-methylpentanoyl)-N-tert-butoxycarbonylhydrazinomethyl]-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-54-7 (3aR,6S,6aS)-1-[(2S)-2-(4-tert-butylbenzoylamino)-4-methylpentanoyl]-6-hydroxyhexahydropyrrolo[3,2-c]pyrazole-2-carboxylic acid tert-butyl ester 
• 648934-43-4 (2S)-2-[N'-((2S)-2-amino-4-methylpentanoyl)-N-tert-butoxycarbonylhydrazinomethyl]-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-32-1 (S)-2-(N-tert-butoxycarbonyl-N'-allyloxycarbonylhydrazinomethyl)-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-27-4 (S)-2-(N'-allyloxycarbonylhydrazinomethyl)-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-35-4 (S)-2-(N-tert-butoxycarbonylhydrazinomethyl)-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-20-7 (S)-2-methanesulfonyloxymethyl-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 
• 648934-22-9 (S)-2-azidomethyl-2,5-dihydropyrrole-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

cis-6-oxo-hexahydro-2-oxa-1,4-diazapentalene and cis-6-oxo- hexahydropyrrolo[3,2-c]pyrazole based scaffolds: Design rationale, synthesis and cysteinyl proteinase inhibition

The 5,5-bicycles cis-6-oxo-hexahydro-2-oxa-1,4-diazapentalene 3 and cis-6-oxo-hexahydropyrrolo[3,2-c]pyrazole 4 were designed as rotationally restricted templates towards the preparation of inhibitors of CAC1 cysteinyl proteinases. The design strategy was

BIOLOGICALLY ACTIVE COMPOUNDS

Compounds of general formula (I) wherein: Z = CR3R4, where R3 and R4 are independently chosen from CO-7-alkyl P1 = CR5R6, P2 = O, CR7R8/sup